ESR 8:Clinical user interface for hyperthermia treatment planning system

Position as a researcher, with the possibility to continue for a PhD when suitable.

Host: Dr. PierFrancesco Pavoni and Dr. H. Petra Kok

Recruiting organisation: Medlogix Srl, via A. Olivetti 24, Rome

Duration: 36 months

 

Background

Hyperthermia enhances the effectiveness of radiotherapy, as has been established in different clinical trials. At the moment patient-specific radiotherapy and hyperthermia treatment settings are each planned in a separate dedicated user interface to achieve a dose distribution which results in optimal treatment outcome while avoiding normal tissue side effects. The Hyperboost project aims at integrating these two separate user interfaces into a single user interface. This will allow making a patient-specific combined treatment plan. Achieving this requires incorporation of all available knowledge on the synergistic actions between hyperthermia and radiotherapy.

Approach 

ESR8 will develop the clinical user interface for the RT+HT treatment planning system including all facilities of existing HT and RT planning systems extended with additional features. These will include capability of handling DICOM format CT or MRI patient datasets; delineation tools for tumor and organs at risk; optional use of biological tumor models with increasing complexity from including just DNA repair inhibition, adding direct cell kill, reoxygenation (in cooperation with ESR5); Patient-specific MR-perfusion imaging for more advanced thermal modelling (in cooperation with ESR12); online adaptive HT planning based on temperature or BED (RT+HT) (in cooperation with ESR6); reconstruction of 3-D temperature distribution (in cooperation with ESR7); evaluation tools of the effective dose distributions of HT, RT and the combination of RT+HT, these will conform existing standards in cooperation with ESR 11.

Our research team

Medlogix designs, produces and sells innovative medical devices, and has expert staff for hardware and software design. We collaborate on customized innovative projects with top academic centers, including University of Tor Vergata (Rome), Czech Technical University (Prague), ErasmusMC (B10, Rotterdam) and Academic Medical Center (B1, Amsterdam). Medlogix srl has an RF lab with RF instruments and equipment, and tools for development of software. Facilities are suitable for supervising the research and training of Early-Stage Researchers. Supervision is provided by Eng. Silvia Ciampa of Medlogix as PI for the clinical implementation, and by Dr H. Petra Kok of AMC, a leading expert in advanced hyperthermia treatment planning.

Your experience

The Researcher will develop an advanced clinical user interface for the radiotherapy (RT) + hyperthermia (HT) treatment planning system including all facilities of existing HT and RT planning systems extended with additional features, which will include tools for:

  • handling imaging data sets
  • tumor delineation
  • temperature reconstruction
  • adaptive planning
  • computation of the biologically equivalent dose of the combined treatment

Specifically, these features will include:

  • use of biological tumor models with increasing complexity from including just DNA repair inhibition, adding direct cell kill, reoxygenation (in cooperation with ESR5);
  • patient-specific MR-perfusion imaging for more advanced thermal modeling (in cooperation with ESR12);
  • online adaptive HT planning based on temperature or BED (RT+HT) (in cooperation with ESR6);
  • reconstruction of 3-D temperature distribution (in cooperation with ESR7);
  • evaluation tools of the effective dose distributions of HT, RT, and the combination of RT+HT. these will conform to existing standards in cooperation with ESR 11.

These features will be adjusted or integrated based on user feedback and ongoing research.

The researcher should be familiar with Python and C++.

Our offer

This position is funded by the Marie Skłodowska-Curie actions of the European Union's Horizon 2020 research and innovation program under grant agreement No 955625.  You will be appointed as fulltime researcher for 3 years with Medlogix. The Marie Skłodowska-Curie (MSCA) programme offers a highly competitive and attractive salary and working conditions. The successful candidates will receive a salary in accordance with the MSCA regulations for early stage researchers. Exact salary will be confirmed upon appointment [Living Allowance = €37.320/year (correction factor to be applied per country) + Monthly mobility allowance = €600. An additional monthly allowance of €500 is applicable depending on family situation. In addition to their individual scientific projects, all fellows will benefit from further continuing education, which includes internships and secondments, a variety of training modules as well as transferable skills courses and active participation in workshops and conferences.

Your application

See recruitment procedure. You can apply using the online application form. For more information about the position you can contact Dr.PierFrancesco Pavoni (This email address is being protected from spambots. You need JavaScript enabled to view it.) at +390640043808 or Dr. H. Petra Kok (This email address is being protected from spambots. You need JavaScript enabled to view it.) at +31 (0)20 56 64231.  

Medlogix Srl, Rome

Medlogix designs, produces and sells innovative hyperthermia systems for oncology, physiotherapy and sports medicine. In a strategic agreement with Restek Srl (Rome), a company founded in 1994, Medlogix began its activities in 2009 with the sale of the ALBA ON 4000 device for superficial hyperthermia. From 2010 onwards Medlogix has started a series of technical and scientific collaborations with several excellent university centers, such as the University of Tor Vergata (Rome, Italy), the AMC/University of Amsterdam (Amsterdam, Netherlands), ErasmusMC (Rotterdam, Netherlands), the Czech Technical University (Prague, Czech Republic), for the development of innovative and technically advanced customized projects in the field of oncological hyperthermia. From the collaborations with these academic institutes, Restek and other trading partners, the Medlogix Srl has managed to develop and market very advanced hyperthermia products for the radiation oncology field, now installed in radiotherapy departments of top cancer hospitals and research centers in Europe and Middle East. From 2012 onwards Medlogix has initiated the project for the construction of the ALBA 4D, the second phased array system for oncological deep hyperthermia in the world, CE marked in 2018. Medlogix is based in Rome’s Tiburtino Technology Park, well known for companies partnering in precision engineering and electronics, radar technology and space telecommunications. Medlogix has expert staff for hardware and software design, dedicated exclusively to the development of innovative technology for hyperthermia in oncology.